NYSE:JNJ

Johnson & Johnson Stock (JNJ) After Hours Today (Dec. 18, 2025): FDA Approvals, Analyst Targets, and Talc Litigation in Focus Ahead of Friday’s Open

Johnson & Johnson finished Thursday’s regular session lower even as the broader market moved higher, then ticked modestly upward in after-hours trading—leaving investors with a familiar year-end setup: solid pipeline/MedTech progress on one side, and talc litigation headlines on the other.

19 December 2025

NYSE:JNJ·Stock Market

Johnson & Johnson Stock (JNJ) News Today: FDA Approvals, Analyst Price Targets, and the 2026 Outlook (Dec. 18, 2025)

Johnson & Johnson stock traded around $208 on Thursday, December 18, 2025, with shares modestly lower on the session as investors weighed a busy late-year news cycle that includes fresh FDA wins in MedTech and oncology, new Wall Street target updates, and the continued legal overhang from talc litigation.

18 December 2025

NYSE:JNJ·Stock Market

Johnson & Johnson Stock After Hours (Dec. 17, 2025): JNJ Closes Higher on FDA News—What to Know Before the Market Opens Thursday

Johnson & Johnson ended Wednesday’s session modestly higher—an eye-catching show of relative strength on a down day for major U.S. indexes—while investors digested a fresh FDA approval tied to the company’s lung cancer franchise and looked ahead to a potentially market-moving inflation print before Thursday’s open.

18 December 2025

NYSE:JNJ·Stock Market

Johnson & Johnson Stock (JNJ) News Today: RBC Raises Target to $240 as FDA Actions and Talc Verdict Shape the 2026 Outlook

CAs of Wednesday, December 17, 2025, Johnson & Johnson is back in focus for investors looking for a “defensive” large-cap healthcare stock—while also weighing two forces that can move JNJ shares quickly: drug pipeline catalysts and talc litigation headlines.

17 December 2025

NYSE:JNJ·Pharmaceuticals

Johnson & Johnson Stock (JNJ) Today: FDA Priority Voucher, Talc Verdict, Earnings Date and 2026 Growth Outlook

December 16, 2025 — Johnson & Johnson stock is trading lower on Tuesday after pushing to fresh highs earlier this week, as investors weigh a mix of pipeline momentum, legal headlines, and an approaching earnings update that could clarify the company’s 2026 trajectory. StockAnalysis+1

16 December 2025

Earnings Reports·NYSE:JNJ·Pharmaceuticals·Stock Market

Johnson & Johnson Stock After Hours (Dec. 15, 2025): JNJ Rises on FDA Priority Voucher — What to Know Before Tuesday’s Open

Johnson & Johnson shares finished Monday, December 15, 2025 higher and held modest gains in extended trading — a notable showing for a defensive blue chip as investors brace for a data-heavy week and shifting rate expectations.

16 December 2025

NYSE:JNJ·Stock Market

Johnson & Johnson Stock (JNJ) Today: FDA Fast‑Track Voucher Lifts Oncology Narrative as Talc Verdict Renews Legal Overhang

Johnson & Johnson stock is starting the week at the center of two storylines that often tug the share price in opposite directions: accelerating momentum in oncology and a stubborn, headline‑driven litigation risk.

15 December 2025

NYSE:JNJ·Pharmaceuticals·Stock Market

Healthcare & Pharma Giants US Stocks: Week Ahead Outlook After Eli Lilly’s Retatrutide, CVS Guidance, Pfizer’s Obesity Deal, and J&J’s Talc Verdict (Updated Dec. 14, 2025)

Wall Street heads into the week of Dec. 15, 2025 with U.S. healthcare and pharma mega-caps back in the spotlight—pulled by three powerful forces that all intensified in the last seven days: the obesity-drug arms race, Washington’s policy crosscurrents around insurance subsidies and PBM transparency, and a faster-moving FDA that is simultaneously accelerating reviews and reopening safety scrutiny in sensitive pediatric categories. Reuters+3Reuters+3Reuters+3

14 December 2025

Earnings·NYSE:CVS·NYSE:JNJ·NYSE:LLY·NYSE:PFE·Pharmaceuticals·US Stocks

Johnson & Johnson Stock (JNJ) Jumps Near 52-Week Highs on FDA Approval and Oncology Data — Week in Review, Week Ahead (Updated Dec. 12, 2025)

Meta description: Johnson & Johnson climbed to $211.58 this week as investors weighed FDA approval news, breakthrough oncology data, and fresh talc-trial risk. Reuters+3Investing.com+3JNJ.com+3

13 December 2025

NYSE:JNJ·Pharmaceuticals·Stock Market

Johnson & Johnson (JNJ) Stock News Today, Forecasts and Analyst Targets (Dec. 12, 2025)

Johnson & Johnson stock is ending the week in the spotlight as shares hover near record territory, helped by a steady stream of analyst target updates, fresh late-stage clinical data disclosures, and a clearer roadmap for portfolio reshaping heading into 2026.

12 December 2025

NYSE:JNJ·Stock Market

Johnson & Johnson (JNJ) Stock Hits New High After the Bell on December 11, 2025 – What to Know Before the December 12 Open

Johnson & Johnson closed regular trading on Thursday, December 11, 2025 at $210.01, up about 1.7% on the day, marking a fresh 52‑week high before easing slightly in after‑hours trading around $209.25. MarketScreener+1

12 December 2025

NYSE:JNJ·Stock Market

Johnson & Johnson (JNJ) Stock Near Record Highs: Latest News, Legal Risks and 2026 Outlook for Investors

Johnson & Johnson stock has gone from sleepy blue chip to market star in 2025. As of the morning of December 11, 2025, JNJ trades around $208 per share, sits at an estimated $500+ billion market capitalization, and is at its 52‑week high after a powerful rally that has outpaced the S&P 500. StockAnalysis+1

11 December 2025

NYSE:JNJ·Stock Market

Johnson & Johnson (JNJ) Stock After the Bell on December 10, 2025 – And What to Watch Before the December 11 Open

Johnson & Johnson stock is back in the market’s spotlight. After a powerful run in 2025, JNJ is now trading just under record highs as investors juggle two very different narratives: blockbuster oncology and immunology growth on one side, and grinding talc litigation plus regulatory noise on the other.

11 December 2025

Earnings Reports·NYSE:JNJ·Stock Market

Johnson & Johnson (JNJ) Stock on December 10, 2025: Pipeline Breakthroughs, Talc Risks and What Analysts Expect Next

Johnson & Johnson is trading near fresh highs as investors weigh powerful growth drivers in oncology and immunology against a still‑messy overhang from talc litigation.

10 December 2025

Financial Forecasts·NYSE:JNJ·Pharmaceuticals·Stock Market

Johnson & Johnson (JNJ) Stock After Hours on December 9, 2025: New Cancer Breakthrough, Dividend Payout and What to Watch Before the December 10 Open

Below, we’ll walk through what happened to Johnson & Johnson stock after the bell on December 9 and what investors should watch before the U.S. market opens on Wednesday, December 10, 2025.

10 December 2025

Dividends·Health News·NYSE:JNJ·Stock Market

Johnson & Johnson Stock Today: Q3 Beat, Orthopaedics Spin-Off and New Cancer Data Power a 40% Rally

Johnson & Johnson stock has quietly turned into one of 2025’s standout blue‑chip winners. As of December 9, 2025, JNJ trades around $202 per share, valuing the company at roughly $486 billion and leaving the stock up close to 40% year to date.Trefis+1

9 December 2025

Earnings Reports·NYSE:JNJ·Stock Market

Eli Lilly (LLY) Stock After Hours on December 8, 2025: China Mounjaro Win, Dividend Hike and What to Watch Before Tuesday’s Open

Eli Lilly and Company spent Monday, December 8, 2025, digesting a wave of news: a major reimbursement win for Mounjaro in China, a 15% dividend hike, new leukemia drug data, and the return of Nobel laureate Carolyn Bertozzi to its board. At the same time, intensifying competition and price cuts in the weight‑loss drug market kept pressure on the stock.

9 December 2025

Dividends·Earnings Reports·NASDAQ:GPCR·NYSE:JNJ·NYSE:LLY·Pharmaceuticals·Stock Market

Johnson & Johnson (JNJ) Stock Outlook 2026: Talc Verdicts, Stelara Cliff and a 40% Rally – What Investors Need to Know Now

Johnson & Johnson is trading around $202–203 per share in New York trading on December 8, 2025. Recent closing data show the stock finished at $202.48 on December 8 after a modest decline of 0.27%.StockAnalysis

8 December 2025

Financial Forecasts·NYSE:JNJ·Pharmaceuticals

Johnson & Johnson (JNJ) Stock Near Record Highs: What to Know Before the Market Opens on December 8, 2025

Johnson & Johnson heads into Monday’s session sitting just below its 52‑week high, with fresh drug data, new access to the Chinese market and ongoing talc litigation all pulling on the share price at once.

8 December 2025

NYSE:JNJ·Stock Market

Johnson & Johnson Stock Today (JNJ): Price, Talc Verdicts, New Bladder Cancer Data and 2026 Outlook – December 6, 2025

Johnson & Johnson stock is ending the first week of December 2025 just below record territory after a powerful year-long rally, driven by a string of earnings beats, major acquisitions in neuroscience and oncology, and fresh clinical data in bladder cancer. At the same time, the company is absorbing huge jury verdicts in talc litigation and preparing to spin off its orthopaedics business, setting up a very different J&J for the second half of the decade. Reuters+4Johnson & Johnson Investor Relations+4Johnson & Johnson Investor Relations+4

6 December 2025

NYSE:JNJ·Pharmaceuticals·Stock Market

NYSE:JNJ 6 December 2025 - 19 December 2025